期刊文献+

丙型肝炎直接抗病毒药物的代谢及药物相互作用 被引量:4

Metabolism and drug interactions of direct-acting antiviral agents for hepatitis C
下载PDF
导出
摘要 直接抗病毒药物(direct-acting antiviral agents,DAAs)的抗HCV疗效显著,但须关注DAAs的不良反应、安全性检测以及与其他药物的相互作用。本文对DAAs的代谢及其与其他药物的相互作用进行综述。 Direct-acting antiviral agents(DAAs) are highly effective in patients with hepatitis C. However, the adverse reactions, safety and drug interactions of the DAAs should be paid much attention. This review focuses on the metabolism and drug interactions of DAAs.
作者 周双男 张敏
出处 《传染病信息》 2016年第2期121-125,共5页 Infectious Disease Information
基金 中国肝炎防治基金会王宝恩肝纤维化研究基金资助课题(2011xjs) 2013年解放军第三〇二医院院长创新基金(YNKT2013021)
关键词 丙型肝炎 抗病毒药 药代动力学 药物相互作用 hepatitis C antiviral agents pharmacokinetics drug interactions
  • 相关文献

参考文献38

  • 1Gower E, EstesC, Biach S, et al. Global epidemiology and genotypedistribution of the hepatitis C virus infection [J] . J Hepatol, 2014,61(1 Suppl):S45-S57.
  • 2European Association for the Study of the Liver. EASL ClinicalPraclice Guidelines: management of hepatitis C virus infection[ j].J Hepatol, 2011, 55(2):245-264.
  • 3Eun)j)ean Association for the Study of the Liver. EASL recommendationson treatment of hepatitis C 2014 [J] . J Hepatol, 2014, 61(2):373-395.
  • 4罗生强.慢性丙型肝炎治疗进展与展望[J].传染病信息,2014,27(4):193-197. 被引量:8
  • 5Vispo E, Barreiro P, Soriano V. Pharmacokinetics of new oralhepatitis C antiviral drugs [J] . Expert Opin Drug Metah Toxicol,2013,9(1):5-16.
  • 6Stedman CA. Current prospe(-ts for interferon-free treatment ofhepatitis C in 2012 [j] . J Gastroenterol Hepatol, 2013, 28(1):38-45.
  • 7KlisiakR, Jaroszewicz J, Parfieniuk-Kovverda A. Krnerging treatmentfor hepatitis C [J] . Expert Opin Emerg Drugs, 2013, 18(4):461-475.
  • 8Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C [J」.J Hepatol, 2013,58(3):583-592.
  • 9Gentile I, Buonomo AR, Zappulo E, et al. Int()rfer(m-free therapiesfor chronic hepatitis C: toward a hepatitis C virus-free world [J].Expert Rev Anti Infect Ther, 2014, 12(7):763-773.
  • 10张霞霞,徐小元.小分子化合物抗丙型肝炎治疗新方案[J].传染病信息,2015,28(4):197-199. 被引量:8

二级参考文献29

  • 1WHO.Guidelines for the screening,care and treatment of persons with hepatitis C infection[EB/OL].[2014-05-06].http://www.who.hiv/pub/ hepatitis-c-guidelines/en/.
  • 2Poordad F,McCone J Jr,Bacon BR,et al.Boceprevir for untreated chronic HCV genotype 1 infection[J].N Engl J Med,2011,364(13):1195-1206.
  • 3Jacobson IM,McHutchison JG,Dusheiko G,et al.Telaprevir for previously untreated chronic hepatitis C virus infection[J].N Engl J Med,2011,364(25):2405-2416.
  • 4Jacobon IM,Gordon SC,Kowdley KV,et al.Sofosbuvir for hepatitis C genotypes 2 or 3 in patients without treatment options[J].N Engl J Med,2013,368(10):1867-1877.
  • 5Gane EJ,Stedman CA,Hyland RH,et al.Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C[J].N Engl J Med,2013,368(1):34-44.
  • 6Asselah T,Marcellin P.Second-wave IFN-based triple therapy for HCV genotype 1 infection:simeprevir,faldaprevir and sofosbuvir[J].Liver Int,2014,34(Suppl 1):S60-S68.
  • 7Clark VC,Peter JA,Nelson DR.New therapeutic strategies in HCV:second-generation protease inhibitors[J].Liver Int,2013,33(Suppl 1):S80-S84.
  • 8EASL.EASL Recommendations on treatment of hepatitis C 2014[EB/OL].[2014-05-06].http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014.
  • 9AASLD.Recommendations for testing,managing,and treating hepa- titis C[EB/OL].[2014-05-06].http://hcvguidelines.org/.
  • 10Smith DB,Bukh J,Kuiken C,et al.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes:updated criteria and genotype assignment Web resource[J].Hepatology,2014,59(1):318-327.

共引文献14

同被引文献36

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部